SCHEMBL20394277

SCHEMBL20394277

COc1ccccc1-c1cccnc1Oc1ccc(C(F)(F)CN(C)OC)nc1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 9/20 0.40
▸ ELANE P08246 1/20 0.35
▸ HTR7 P34969 1/20 0.34
▸ GPBAR1 Q8TDU6 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PPP1CA P62136 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394266 0.92 PDE10A (0.41) PDE10AELANEHTR7GPBAR1ALDH1A1
SCHEMBL20394425 0.89 PDE10A (0.40) PDE10AELANEHTR7GPBAR1
SCHEMBL20406787 0.87 PDE10A (0.39) PDE10AELANEHTR7GPBAR1
SCHEMBL20394508 0.87 PDE10A (0.44) PDE10AELANEGPBAR1ALDH1A1
SCHEMBL20394430 0.87 PDE10A (0.44) PDE10AGPBAR1
SCHEMBL20406434 0.86 PDE10A (0.43) PDE10AGPBAR1ALDH1A1
SCHEMBL20394448 0.85 PDE10A (0.45) PDE10AELANEALDH1A1LMNASMN1; SMN2
SCHEMBL18661455 0.85 PDE10A (0.43) PDE10AELANEALDH1A1LMNASMN1; SMN2
SCHEMBL18661517 0.84 PDE10A (0.46) PDE10AELANEALDH1A1LMNASMN1; SMN2
SCHEMBL20394197 0.84 PDE10A (0.41) PDE10AELANEALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 — — EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 — — US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 — — US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 — — US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 — — US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 — — EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA PDE10A 4605/4885ELANE 1638/4885HTR7 1965/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA PDE10A 4605/4885ELANE 1638/4885HTR7 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback